VIRONGY L L C has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are AGNEW BRIAN, SCHUPPAN DETLEF and SHANDONG LVDU BIO SICIENCE & TECH CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | China | 3 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Materials and metallurgy |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Therapeutic chemical compounds | |
#6 | Non-metallic elements |
# | Name | Total Patents |
---|---|---|
#1 | Wu Yuntao | 11 |
#2 | Shang Hong | 4 |
#3 | Fu Yajing | 4 |
#4 | Zidu Zhang | 1 |
#5 | Zhang Zidu | 1 |
#6 | Yuntao Wu | 1 |
Publication | Filing date | Title |
---|---|---|
US2020299139A1 | Compositions and methods for using activated carbon particles for purification of nucleic acids | |
WO2020154359A1 | Cofilin phosphorylation for cancer treatment | |
CN112055715A | Quantitative detection of CD4T cell injury and prediction of CD4T cell recovery following antiretroviral therapy using COFILIN phosphorylation | |
WO2018126042A1 | Retro- and lenti-hbv hybrid vectors and constructs | |
US2018172629A1 | Electrophoresis apparatus and use thereof | |
US2018002390A1 | Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens |